home / stock / pavmz / pavmz news

PAVMZ News and Press, PAVmed Inc. Series Z Warrant From 05/11/20

Stock Information
Company Name: PAVmed Inc. Series Z Warrant
Stock Symbol: PAVMZ
Market: NASDAQ
Website: pavmed.com
Menu
PAVMZ PAVMZ Quote PAVMZ Short PAVMZ News PAVMZ Articles PAVMZ Message Board
Get PAVMZ Alerts

News, Short Squeeze, Breakout and More Instantly...
PAVMZ - PAVmed to Hold Business Update Conference Call on May 21, 2020

NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will host a business update conference call on Thursday, May...
PAVMZ - PAVmed Receives FDA 510(k) Clearance for its CarpX(TM) Minimally Invasive Carpal Tunnel Device

NEW YORK, April 21, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has received 510(k) marketing clearance from the U.S. Food and Drug Admi...

PAVMZ - PAVmed Reports Preliminary Fourth Quarter 2019 Financial Results and Provides Business Update

Conference call to be held today at 4:30 p.m. Eastern time NEW YORK, April 09, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported preliminary f...

PAVMZ - PAVmed Subsidiary Lucid Diagnostics' EsoCheck Esophageal Cell Collection Device Receives Prestigious Edison Best New Product Award

NEW YORK, April 02, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the EsoCheck™ Esophageal Cell Collection Device with Collect+Pr...
PAVMZ - PAVmed Receives $6.3 Million in Gross Proceeds from Completion of November 2019 Financing

NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has received $6.3 million in new gross proceeds from the prepayment of p...

PAVMZ - PAVmed to Hold Business Update Conference Call on April 9, 2020

NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will report fourth quarter 2019 financial results after th...

PAVMZ - PAVmed Announces FDA 510(k) Re-submission for its CarpX(TM) Minimally Invasive Carpal Tunnel Device

Incorporates data from successful clinical safety study in which all patients met pre-specified safety and effectiveness endpoints NEW YORK, March 09, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differen...
PAVMZ - PAVmed Subsidiary Lucid Diagnostics Partners with Fred Hutchinson Cancer Research Center to Evaluate Barrett's Esophagus (BE) Progression Biomarkers Using EsoCheck(TM)

Lucid secures exclusive option to license biomarker technology to detect progression from nondysplastic to dysplastic BE using EsoCheck to allow curative ablation before deadly esophageal cancer develops NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (t...

PAVMZ - PAVmed Adds EsoCure(TM) Esophageal Ablation Device with Patented Caldus(TM) Technology to Commercial Product Pipeline

Disposable single-use device designed to provide safer, more efficient and cost-effective ablation of dysplastic Barrett’s Esophagus, complementing Lucid Diagnostics’ EsoGuard ™ and EsoCheck ™ products NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc...

PAVMZ - U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test

NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company’s majority owned subsidiary, Lucid Diagnostics Inc. ...
Previous 10 Next 10